Cargando…
Discovery of a Novel Hybrid of Vorinostat and Riluzole as a Potent Antitumor Agent
Vorinostat (suberoylanilide hydroxamic acid) was the first approved histone deacetylase (HDAC) inhibitor in a group of validated cancer therapeutic agents targeting epigenetics. Riluzole is a drug used to treat amyotrophic lateral sclerosis, the antitumor potency of which has been recently revealed....
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7375020/ https://www.ncbi.nlm.nih.gov/pubmed/32760715 http://dx.doi.org/10.3389/fcell.2020.00454 |